Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium

Biochemical and Biophysical Research Communications

Volumn 373, Issue 2, 2008, Pages 253-257

  Baden, Tatsuya ^a   Yamawaki, Hideyuki ^a   Saito, Kazuaki ^a   Mukohda, Masashi ^a   Okada, Muneyoshi ^a   Hara, Yukio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blocker; Apoptosis; Diabetes; Endothelial cell; Glucose metabolite

Indexed keywords

CASPASE 3; METHYLGLYOXAL; TELMISARTAN;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TIME; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; APOPTOSIS; BENZIMIDAZOLES; BENZOATES; CASPASE 3; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HUMANS; PYRUVALDEHYDE;

EID: 46049090742     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.06.023     Document Type: Article

References (32)

1. Phillips S.A., and Thornalley P.J. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur. J. Biochem. 212 (1993) 101-105
2. Ahmed M.U., Brinkmann Frye E., Degenhardt T.P., Thorpe S.R., and Baynes J.W. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem. J. 324 Pt 2 (1997) 565-570
3. Lapolla A., Flamini R., Dalla Vedova A., Senesi A., Reitano R., Fedele D., Basso E., Seraglia R., and Traldi P. Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin. Chem. Lab. Med. 41 (2003) 1166-1173
4. Kilhovd B.K., Giardino I., Torjesen P.A., Birkeland K.I., Berg T.J., Thornalley P.J., Brownlee M., and Hanssen K.F. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52 (2003) 163-167
5. Fosmark D.S., Torjesen P.A., Kilhovd B.K., Berg T.J., Sandvik L., Hanssen K.F., Agardh C.D., and Agardh E. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 55 (2006) 232-236
6. Mostafa A.A., Randell E.W., Vasdev S.C., Gill V.D., Han Y., Gadag V., Raouf A.A., and El Said H. Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol. Cell. Biochem. 302 (2007) 35-42
7. Wu L. Is methylglyoxal a causative factor for hypertension development?. Can. J. Physiol. Pharmacol. 84 (2006) 129-139
8. Wienen W., Hauel N., Van Meel J.C., Narr B., Ries U., and Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol. 110 (1993) 245-252
9. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., and Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
10. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., and Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
11. Young J.B., Dunlap M.E., Pfeffer M.A., Probstfield J.L., Cohen-Solal A., Dietz R., Granger C.B., Hradec J., Kuch J., McKelvie R.S., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Held P., Solomon S.D., Yusuf S., and Swedberg K. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110 (2004) 2618-2626
12. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P., and Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358 (2008) 1547-1559
13. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
14. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
15. Yamawaki H., and Hara Y. Glyoxal causes inflammatory injury in human vascular endothelial cells. Biochem. Biophys. Res. Commun. 369 (2008) 1155-1159
16. Yamawaki H., Pan S., Lee R.T., and Berk B.C. Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J. Clin. Invest. 115 (2005) 733-738
17. Yamawaki H., and Iwai N. Cytotoxicity of water-soluble fullerene in vascular endothelial cells. Am. J. Physiol. Cell Physiol. 290 (2006) C1495-C1502
18. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
19. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
20. Du J., Suzuki H., Nagase F., Akhand A.A., Yokoyama T., Miyata T., Kurokawa K., and Nakashima I. Methylglyoxal induces apoptosis in Jurkat leukemia T cells by activating c-Jun N-terminal kinase. J. Cell. Biochem. 77 (2000) 333-344
21. Du J., Suzuki H., Nagase F., Akhand A.A., Ma X.Y., Yokoyama T., Miyata T., and Nakashima I. Superoxide-mediated early oxidation and activation of ASK1 are important for initiating methylglyoxal-induced apoptosis process. Free Radic. Biol. Med. 31 (2001) 469-478
22. Ota K., Nakamura J., Li W., Kozakae M., Watarai A., Nakamura N., Yasuda Y., Nakashima E., Naruse K., Watabe K., Kato K., Oiso Y., and Hamada Y. Metformin prevents methylglyoxal-induced apoptosis of mouse Schwann cells. Biochem. Biophys Res. Commun. 357 (2007) 270-275
23. Fukunaga M., Miyata S., Liu B.F., Miyazaki H., Hirota Y., Higo S., Hamada Y., Ueyama S., and Kasuga M. Methylglyoxal induces apoptosis through activation of p38 MAPK in rat Schwann cells. Biochem. Biophys. Res. Commun. 320 (2004) 689-695
24. Hsieh C.L., Huang C.N., Lin Y.C., and Peng R.Y. Molecular action mechanism against apoptosis by aqueous extract from guava budding leaves elucidated with human umbilical vein endothelial cell (HUVEC) model. J. Agric. Food Chem. 55 (2007) 8523-8533
25. Kim J., Son J.W., Lee J.A., Oh Y.S., and Shinn S.H. Methylglyoxal induces apoptosis mediated by reactive oxygen species in bovine retinal pericytes. J. Korean Med. Sci. 19 (2004) 95-100
26. Rong Y., Doctrow S.R., Tocco G., and Baudry M. EUK-134, a synthetic superoxide dismutase and catalase mimetic, prevents oxidative stress and attenuates kainate-induced neuropathology. Proc. Natl. Acad. Sci. USA 96 (1999) 9897-9902
27. Thornalley P.J. Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochem. Soc. Trans. 31 (2003) 1372-1377
28. Li D., Yang B., Philips M.I., and Mehta J.L. Proapoptotic effects of ANG II in human coronary artery endothelial cells: role of AT1 receptor and PKC activation. Am. J. Physiol. 276 (1999) H786-H792
29. Artwohl M., Holzenbein T., Furnsinn C., Freudenthaler A., Huttary N., Waldhausl W.K., and Baumgartner-Parzer S.M. Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. Thromb. Haemost. 93 (2005) 810-815
30. Imayama I., Ichiki T., Inanaga K., Ohtsubo H., Fukuyama K., Ono H., Hashiguchi Y., and Sunagawa K. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc. Res. 72 (2006) 184-190
31. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43 (1991) 109-142
32. Ikejima H., Imanishi T., Tsujioka H., Kuroi A., Kobayashi K., Shiomi M., Muragaki Y., Mochizuki S., Goto M., Yoshida K., and Akasaka T. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J. Hypertens. 26 (2008) 964-972